| Literature DB >> 20806367 |
Brian Belyea1, Ashley Hinson, Cassandra Moran, Eugene Hwang, Jessica Heath, Raymond Barfield.
Abstract
Secondary hemophagocytic lymphohistiocytosis (sHLH) is a reactive, proliferative disorder of the immune system resulting in lymphohistiocytic proliferation, hemophagocytosis, and cytokine dysregulation. The most common infectious trigger in sHLH is Epstein-Barr virus (EBV-HLH). Current treatment protocols for EBV-HLH have a cure rate of approximately 75%; however, there are significant toxicities associated with these therapies. We present two patients with EBV-HLH who experienced spontaneous resolution of their disease prior to the initiation of therapy, suggesting there may be a subgroup of patients with EBV-HLH who do well with conservative management and can avoid potentially toxic therapies. Copyright 2010 Wiley-Liss, Inc.Entities:
Mesh:
Year: 2010 PMID: 20806367 DOI: 10.1002/pbc.22618
Source DB: PubMed Journal: Pediatr Blood Cancer ISSN: 1545-5009 Impact factor: 3.167